Heart failure (HF) is a problem of epidemic proportions in Western societies; it is
a major public health burden and source of morbidity and mortality. Traditionally,
HF has been categorised according to left ventricular systolic function. Patients
with heart failure and left ventricular ejection fraction (LVEF) < 40% have been referred
to as having HF with reduced ejection fraction (HFrEF), and those with higher LVEF
as having HF with preserved ejection fraction (HFpEF). Although these two HF types
are quite similar in terms of clinical presentation, rate of hospitalisation, quality
of life, and symptom and caregiver burdens, fundamental differences remain.
1
Unlike HFrEF, for which 6 approved medication classes exist for treatment to reduce
CV mortality, there are no approved therapies for the nearly 300,000 patients with
HFpEF in Canada. In addition, HFpEF is increasingly common and is responsible for
approximately 50% of prevalent HF and for 75,000 annual hospitalisations in Canada.
This has resulted in a large unmet clinical need for patients affected by HFpEF.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Canadian Journal of CardiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Heart failure with midrange ejection fraction—what is it, if anything?.Can J Cardiol. 2021; 37: 585-594
- Angiotensin-neprilysin inhibition versus enalapril in heart failure.N Engl J Med. 2014; 371: 993-1004
- Sacubitril/valsartan across the spectrum of ejection fraction in heart failure.Circulation. 2020; 141: 352-361
- Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum.Eur J Heart Fail. 2018; 20: 1230-1239
- Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction.Eur Heart J. 2016; 37: 455-462
Article info
Publication history
Published online: January 19, 2021
Accepted:
January 13,
2021
Received:
January 10,
2021
Footnotes
See page 529 for disclosure information.
Identification
Copyright
© 2021 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.
